

A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer

Amandine Maulard, Cyrus Chargari, Matthieu Faron, Asim Alwohaibi, Alexandra Leary, Patricia Pautier, Catherine Genestie, Philippe Morice, Sebastien Gouy

▶ To cite this version:

Amandine Maulard, Cyrus Chargari, Matthieu Faron, Asim Alwohaibi, Alexandra Leary, et al.. A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer. Gynecologic Oncology, 2020, 159, pp.534 - 538. 10.1016/j.ygyno.2020.08.002 . hal-03493045

HAL Id: hal-03493045 https://hal.science/hal-03493045

Submitted on 24 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

A new score based on biomarker values to predict the prognosis of locally
 advanced cervical cancer:

- Amandine MAULARD M.D.,^a Cyrus CHARGARI M.D.,^{b,c,d} Ph.D, Matthieu FARON
 M.D,Ph.D,^e Asim ALWOHAIBI, MD,^a, Alexandra LEARY M.D., Ph.D,^f Patricia
 PAUTIER M.D.,^f Catherine GENESTIE M.D.,^g Philippe MORICE M.D.,Ph.D,^{a,d,h}
 Sebastien GOUY M.D., Ph.D..^a
- From the Department of Gynecologic Surgery, Gustave Roussy, Villejuif France,^a
 the Department of Radiotherapy and Brachytherapy Unit,^b Effets biologiques des
 rayonnements, Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge,
 France,^c University Paris Sud,^d the Department of Digestive Surgery, Gustave
 Roussy, Villejuif France,^e the Department of Medical Oncology, Gustave Roussy,
 Villejuif France,^f the Department of Pathology, Gustave Roussy, Villejuif France,^g Unit
 INSERM 1030, Villejuif France.^h
- 16

1

- 17
- 18 Correspondence and requests for reprints:
- 19 Dr. Sebastien Gouy
- 20 Institute Gustave Roussy 114 Rue Edouard Vaillant Villejuif 94805 France
- 21 Email: sebastien.gouy@gustaveroussy.fr

24 Highlights

- pretreatment values of leucocyte, platelet and hemoglobin.
- prospective study of 238 patients treated for locally advanced cervical cancer.
- our score includes 3 biomarkers permit to identify patients with high risk of relapse.

- 66
- 67
- 68 69

70 **ABSTRACT**

71

72 **Objective:** To define a prognostic score based on pretreatment values of leucocyte,

73 platelet and hemoglobin in locally advanced cervical cancer (LACC).

Material and methods: We conducted a prospective study of 238 patients for LACC with negative PET imaging in the para-aortic (PA) area and who were undergoing laparoscopic PA lymphadenectomies. All patients were treated with chemo-radiation and brachytherapy.

Results: Patients had clinical International Federation of Gynecology and Obstetrics stages IB2 (n =76), IIA (n=13), IIB (n=122), III (n=18) or IVA (n=9). We identified three biological parameters (at the time of diagnosis) with three cut-offs which impacted disease free survival (DFS) and overall survival (OS) : <12 g/dL for hemoglobin, >10,000/ μ L for leucocyte and >300x109/L for platelet. A score is calculated, as shown in the table below, by adding the scores of all three biological parameters together (with a maximum score of three).

Score	0	1
Hemoglobin	≥12g/dl	<12 g/dl
Leucocyte	<u>≤</u> 10,000/μL	>10,000/µL
Platelet	<300x109/L	<u>></u> 300x109/L
Total score	/3	

85

DFS at 36 months was 87.3% [78.3-97.4], 58% [45-74.6], 79.1% [71.1-88], 58% [45-74.6] and 56.8% [37.8-85.4] for scores of 0, 1, 2 and 3 respectively. OS at 36 months
was 92.6% [84.9-100], 84% [76.6-92.1], 62.5% [48.9-79.9] and 67% [46.8-96] for
scores of 0, 1, 2 and 3 respectively.

90	Conclusion: This score includes three biomarkers with easily remembered cut-offs
91	that allow us to identify, at the time of diagnosis, those patients with a high risk of
92	relapse (scores of two or three) and those requiring dose escalation.
93	
94	
95	
96	

97 INTRODUCTION

98

For locally advanced cervical cancer (LACC), Chemoradiotherapy (CRT) is 99 100 considered the standard treatment by many North American and European teams.¹ In 2018, the Phase III trial (NCT00193739), which compared CRT and neoadjuvant 101 chemotherapy followed by radical surgery, confirmed the superiority of CRT in 102 LACC.² Despite CRT, the 5-year Disease Free Survival rate was 76.7%. In this 103 104 Phase III trial², the location of relapse was local in 6 %, at a distance in 6.9% and both in 7.6%. To improve local control, new radiation therapy modalities such as 105 image-guided brachytherapy were used.³ To improve distance control, positron 106 emission tomography (PET) imaging at initial diagnosis can be used as a triage to 107 identify patients with metastasis at a distance, especially in the para-aortic nodes, 108 which is the first prognostic factor of survival in LACC.^{4,5} Moreover, for patients with 109 negative PET in para-aortic, a laparascopic para-aortic lymphadenectomy can be 110 used to identify patients with metastasis of less than 5 mm. Indeed, the extension of 111 radiation fields in the para-aortic areas offered the same survival to those patients as 112 that for patients with negative para-aortic nodes.⁶ Due to the inflammation caused by 113 cervical cancer, biological parameters at diagnosis (including neutrophil, leukocyte, 114 platelet and C-reactive protein) have been shown to be prognostic factors.7-9 115 Moreover, anemia has long been identified as an independent prognostic factor.¹⁰ 116 The challenge was how to use these biological parameters to identify, at the time of 117 diagnosis, those patients with a high risk of relapse and those requiring dose 118 escalation. At the time of relapse Moore et al., developed a model based on five 119 factors (race, PS, site of disease, prior radiosensitizer and interval between diagnosis 120 and first recurrence) to predict the response to chemotherapy.¹¹ The Moore criteria 121

were prospectively validated by Tewari et al., to evaluate the benefit of the incorpation of bevacizumab with chemotherapy for relapse.¹² The aim of this study is to define a simple score using biological parameters at the time of diagnosis of LACC, to increase the quality of triage of patients.

126

127 **METHODS**

128 Patients

We prospectively included all patients with a diagnosis of LACC and the following 129 criteria: stages IB2 to IVA cervical cancer (according to the 2009 International 130 Federation of Gynecology and Obstetrics classification); classical histology as 131 adenocarcinoma, squamous cell carcinoma or adenosquamous subtypes; no 132 hemotologic malignancies, chronic infection or immunological disease; 133 no extrapelvic disease on conventional imaging (abdominopelvic magnetic resonance 134 imaging [MRI] or CT scan and pelvic MRI) and no PA (or extrapelvic) uptake on initial 135 PET-CT imaging. No peritoneal carcinomatosis or ovarian metastasis at the 136 laparoscopic staging which was done in order to perform a para-aortic 137 lymphadenectomy. 138

139

140 Treatment

The cervical tumor was treated (if there was no PA node involvement after a staging laparoscopy) with pelvic external radiation therapy (45 to 50 Gy) with concomitant platinum-based chemotherapy (cisplatin at a dose of 40 mg/m2 per week). Patients with histologic PA node metastasis after staging laparoscopic surgery were treated

using pelvic and PA CRT (45 to 60 Gy) with concomitant chemotherapy. This 145 146 treatment could be then completed by a 15-Gy dose of uterovaginal brachytherapy (according to the International Commission on Radiation Units recommendations). A 147 boost of external radiation therapy (up to 60 Gy) was optional in patients with 148 suspicious pelvic nodes (on conventional or PET-CT imaging) and/or in patients with 149 initial parametrial involvement. Completion surgery was only used if brachytherapy 150 151 was not technically feasible or on patients exhibiting clinical and radiological (using MRI exams) residual disease six to eight weeks after the end of brachytherapy. 152

153

154 Definition of leukocyte, platelet and hemoglobin disorders

All patients had a blood sample at the diagnosis of cervical cancer, prior to laparoscopic para-aortic staging, which was the first step of the treatment. Anemia was defined with thresholds of 12g/dl. Leukocytosis was defined as a leukocyte count exceeding 10 000/µl. The platelet disorder was defined as a platelet count exceeding 400x109/L.

160

161

162 Follow-ups and statistical analyses :

Follow-ups were scheduled every three months for two years, then every six months for three years and finally, once a year. Quantitative variables were described as mean (+/- sd) and compared with the Student's t-test or as median (IQR) and compared with the Wilcoxon's test depending on the assumption of normality. Qualitative variables were described as counts (percentages) and compared with the

Chi² test or Fisher's exact test as appropriate. Survival curves were calculated 168 according to Kaplan-Meier and compared with the log-rank test from the date of 169 treatment initiation to the date of: death for overall survival and death or first 170 recurrence (whichever came first) for disease-free survival. The impact of quantitative 171 variables on survival was estimated by a single variable Cox proportional hazard 172 model with a restricted cubic spline to assess the monotonicity of the relation. Cut-173 offs were initially defined at the limits of laboratory normal values and subsequently 174 estimated by a sensitivity analysis of the value, maximizing the difference between 175 the curves. Hazard ratios and their 95% confidence intervals were estimated with a 176 177 Cox PH model. All tests were bilateral and a p value lower than .05 was used to denote statistical significance. All analyses were done with R 3.4.4 (The R Core 178 Team, Vienna, Austria). 179

180

181

182 **RESULTS**

183 Patients

We included 238 patients. Table 1 shows patient characteristics. The mean age was 184 45.9 years (+/- 9.9). The tumor histological type was squamous cell carcinoma in 189 185 (80%) patients. Patients had clinical International Federation of Gynecology and 186 Obstetrics stages IB2 (n =76), IIA (n=13), IIB (n=122), III (n=18), or IVA (n=9). The 187 median tumor size was 48.9 mm (range 6 to 120). PET scans were done in the 188 median time of 8.97 days after the first consultation; staging laparoscopic surgeries in 189 the median time of 24 days. PET scans were positive in pelvic nodes for 89 patients 190 (37.5%). After staging surgery, 21 patients (14%) had PA positive nodes. Sixteen 191 hysterectomies (6.7%) were done after brachytherapy for suspicious residual tumors 192

on MRI 6 to 8 weeks after treatment. For only 6 patients (2.5%), histological residual
tumors were found. The median follow-up was 53 months [range 48-59]. The rate of
relapse was 22% with a median time of 8.24 months (range 0.03 to 67.9). Table 2
lists the localization of recurrence..

197 Leukocyte, platelet and hemoglobin disorders and statistical analysis

We identified three cut-offs which impacted disease free survival and overall survival: <12 g/dL for hemoglobin; $>10,000/\mu$ L for leucocyte; >300x109/L for platelet. For each of the three biological parameters a score of "0" or "1". A score of "1" is given for anemia (<12 g/dL), leukocytosis (>10,000/\muL) and platelet $\ge300x109/L$. A score of "0" is given for hemoglobin $\ge12g/dl$, leucocyte $\le10,000/\mu$ L and platelet <300x109/LThe score is calculated by adding the scores of all three biological parameters together (with a maximum score of three).

Table 3 showed multivariate analysis including our score.

This score at the time of diagnosis is a prognosis of disease free survival and overall survival as shown in Figures 1 and 2 respectively.

The PFS for patients with a score of 0 was 94.1 % [87.8-100], 87.3% [78.3-97.4]
87.3% [78.3-97.4] at 12, 36 and 60 months respectively. The PFS for patients with a
score of 1 was 91.7% [86.4-97.4], 79.1% [71.1-88] and 73.1 % [64.1-83.4] at 12, 36
and 60 months respectively. The PFS for patients with a score of 2 was 72.5% [60.786.5], 58% [45-74.6], and 55.1% [42-72.2] at 12, 36 and 60 months respectively]. The
PFS for patients with a score of 3 was 63.9% [45.7-89.4], 56.8% [37.8-85.4], and
56.8% [37.8-85.4] at 12, 36 and 60 months respectively].

The OS for patients with a score of 0 was 100 % [100-100], 92.6% [84.9-100] and 92.6% [84.9-100] at 12, 36 and 60 months respectively. The OS for patients with a

score of 1 was 99% [97-100], 84% [76.6-92.1] and 82.3% [74.4-91] at 12, 36 and 60
months respectively. The OS for patients with a score of 2 was 89.2% [80.7-98.6],
62.5% [48.9-79.9], and 62.5% [48.9-79.9] at 12, 36 and 60 months respectively. The
OS for patients with a score of 3 was 100% [100-100], 67% [46.8-96], and 58.7%
[37.6-91.5] at 12, 36 and 60 months respectively.

- 222
- 223
- 224

225 **DISCUSSION**

In our retrospective series, we suggested a prognostic score based on leucocyte, 226 platelet and hemoglobin in locally advanced cervical cancer. Our score was easily 227 used in routine practice due to the cut-offs we defined: anemia for hemoglobin 228 (<12g/dl = 1 point), leukocytosis for leucocyte (>10 000/ μ l =1 point) and platelet 229 \geq 300x109/L (= 1 point). In routine practice, our score could be used as a triage to 230 define patients with two or three points as at high risk of relapse. Indeed, patients 231 with two or three points in our score had a dramatic decline of PFS and OS. In the 232 literature, pre-treatment platelet, leukocyte and hemoglobin were all noted as 233 234 prognostic factors.

235

236 Platelet

237 Cheng et al., recently published a meta-analysis and showed that a pretreatment 238 thrombocytosis was an independent prognostic factor in cervical cancer. 239 Unsurprisingly, the author found that pretreatment thrombocytosis was significantly 240 associated with the FIGO stage, pelvic node status and tumor size. Unfortunately, 241 the author did not give a platelet cut-off. The studies, which were included in the

meta-analysis, suggested a platelet cut-off ranging from 272 x109/L to 400 x109/L.8 242 243 Kozasa et al., suggested a cut-off at 350 x109/L as an independent prognostic factor in a series of 684 patients which included 306 stage IIB-IVB treated with 244 radiotherapy followed by brachytherapy with or without chemotherapy.¹³ Moreover, 245 the author showed that platelet count was significantly superior in terms of prognosis 246 than a ratio between platelet and lymphocyte.¹³ Indeed, two studies showed that the 247 platelet-lymphocyte ratio was an independent prognostic factor of OS (Zheng et al.,) 248 and PFS and OS (Chen et al.,) but the two series only included early stage cervical 249 cancer patients who underwent surgical treatment.¹⁴⁻¹⁵ For our score, we chose a 250 251 cut- off for platelet at 300x109/L.

252

253 Leukocyte

Okazawa-Sakai analysed a series of 219 patients with LACC who were treated with 254 radiotherapy. The multivariate analysis identified pelvic node metastasis, pre-255 treatment leukocytosis and pre-treatment neutrophilia as prognosis factors of distant 256 relapse. Leukocytosis > 10 000/ μ l and neutrophils count > 7,500/ μ l were identified as 257 cut-offs.¹⁶ In the era of chemoradiation, our team published a series which included 258 113 patients with LACC who were also treated with brachytherapy. In a multivariate 259 analysis, we found the same cut-off for neutrophils count ($\geq 7,500/\mu$ l).⁹ For our score, 260 we chose leukocyte with a cut-off defined at \geq 10 000/µl which was defined as 261 262 leukocytosis in non-hematological malignancies.¹⁵

263

264

265 Hemoglobin

In 1999, Grogan et al., published a series of 605 patients with LACC who were 266 treated with radiotherapy (11% received concurrent chemotherapy). The authors 267 showed that the increase of survival from a hemoglobin level <12 g/dl to a level 268 >12g/dl was 12%.10 In 2017, Koulis et al., published a series of 257 LACC treated 269 with chemoradiation followed by brachytherapy (in 98%).¹⁸ In a multivariate analysis, 270 an anemia at diagnosis (defined by a hemoglobin ≤ 11.5 g/L) was independently 271 associated with survival (Hazard Ratio 2.76 (1.79 - 4.25) p <0.001).¹⁷ For our 272 score we chose 12 g/dl. Indeed, according to the World Health Organization (WHO), 273 anemia is defined as hemoglobin (Hb) levels <12.0 g/dL in non-pregnant women.¹⁹ 274

275

276 Score and nomogram

Zheng et al., suggested a nomogram to predict overall survival for early cervical 277 cancer stage (IA1 to IIA). This nomogram included platelet, leucocyte and 278 hemoglobin with cut-offs at 217 x109/L, 110 g/L and 7,800/µL respectively. This 279 nomogram was not tested in LACC. Furthermore, this series did not include data 280 about treatment as doses of radiotherapy with or without chemotherapy and external 281 boosts.²⁰ Koulis et al., in a series of 257 LAAC, showed that (on multivariate analysis) 282 283 there was an additional risk of worse PFS 72% vs 42%, [HR 3.05 (95% CI 1.75-5.35), p < 0.001]and OS 68% vs 37% [HR 3.91 (95% CI 2.00–6.49), p < 0.001] at five 284 years in patients who had both pre-treatment anemia (defined by an hemoglobin 285 \leq 11,5 g/L) and leukocytosis (> 10 000/µl).¹⁸ 286

Our score has several advantages. Firstly, it is robust due to the number of patients (n=237) who were treated with the same protocols using PET-CT (to ovoid patients

with para-aortic or distant metastasis) followed by a laparoscopic staging (to ovoid 289 290 patients with peritoneal carcinomatosis), chemoradiation followed by brachytherapy with the same modalities. Secondly, our score is simple due to our defined cut- offs : 291 10 000/µl for leukocytosis and 12 g/dl for hemoglobin (according to the WHO 292 definitions) and 300x109/L for platelet. Thirdly, our score can identify patients with a 293 high risk of relapse (patients with scores of two or three) at the time of diagnosis and 294 may be benefit dose escalation as neoadjuvant chemotherapy, targeted therapy or 295 immunotherapy. Two ongoing studies will give us data on new strategies using 296 chemotherapy. The Phase III Interlace is evaluating weekly induction chemotherapy 297 followed by standard chemoradiation versus standard chemoradioation alone.²¹ The 298 Phase III Outback trial is evaluating adjuvant chemotherapy following CRT as primary 299 treatment for locally advanced cervical cancer compared to CRT alone. This study 300 uses 4 cycles of carboplatin/paclitaxel.²² Bevacizumab with chemotherapy 301 significantly increased overall survival in first relapse.²³ Moreover, Bevacizumab 302 303 alone significantly increased overall survival in second or more lines of chemotherapy.²⁴ Due to those results, Bevacizumab could be an option as an 304 adjuvant treatment after CRT in patients identifying as at high risk of relapse 305 (according to our score). The rationale for immunotherapy was supported by the rate 306 of PD-L1 in squamous cell carcinoma. One ongoing Phase I trial is evaluating 307 Ipilimumab in the primary treatment of LACC. This study will define the best dose of 308 Ipilimumab to give together with CRT.²⁵ 309

310

311 CONCLUSION

312	Our score is simple and easy to use in routine practice. Our score includes three
313	biological parameters with easily remembered cut-offs: leukocytosis > 10 000/ μ l,
314	hemoglobin <12.0 g/dL and platelet> 300×109 /L. Our score can identify, at the time
315	of diagnosis, those patients with a high risk of relapse (scores of two or three) and
316	those requiring dose escalation.
317	
318	
319	Conflict of interest statement
320	Gouy and Morice: Consultancy for Roche
321	Maulard, Chargari, Pautier, Leary, Faron, Genestie, Alwohaibi: no conflict
322	
323	
324	No funding
325	
326	
327	
328	
329	BIBLIOGRAPHY
330 331 332 333 334 335	 Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration: Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J, Gulia S, Kumar N,
226	Shylasree TS, Gawade B, Kembhayi V, Gaikar M, Menon S, Thakur M

Shylasree TS, Gawade R, Kembhavi Y, Gaikar M, Menon S, Thakur M,
Shrivastava S, Badwe R. Neoadjuvant Chemotherapy Followed by Radical
Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients
With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized
Controlled Trial. J Clin Oncol. 2018 Feb 12:JCO2017759985

- 341
 Castelnau-Marchand P, Chargari C, Maroun P, Dumas I, Del Campo ER, Cao
 K, Petit C, Martinetti F, Tafo-Guemnie A, Lefkopoulos D, Morice P, Haie Meder C, Mazeron R. Clinical outcomes of definitive chemoradiation followed
 by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in
 locally advanced cervical cancer. Gynecol Oncol. 2015 Nov;139(2):288-94
- 4. Shen WC, Chen SW, Liang JA, Hsieh TC, Yen KY, Kao CH.
 [18]Fluorodeoxyglucose Positron Emission Tomography for the Textural
 Features of Cervical Cancer Associated with Lymph Node Metastasis and
 Histological Type. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1721-1731.
- Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC.
 Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer.
 1991 Jun 1;67(11):2776-85.
- Gouy S, Morice P, Narducci F, Uzan C, Martinez A, Rey A, Bentivegna E,
 Pautier P, Deandreis D, Querleu D, Haie-Meder C, Leblanc E. Prospective
 multicenter study evaluating the survival of patients with locally advanced
 cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before
 chemoradiotherapy in the era of positron emission tomography imaging. J Clin
 Oncol. 2013 Aug 20;31(24):3026-33
- 360
 7. Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the
 361 neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic
 362 cancers? A systematic review and meta-analysis. Gynecol Oncol. 2017
 363 Jun;145(3):584-594
- Cheng J, Zeng Z, Ye Q, Zhang Y, Yan R, Liang C, Wang J, Li M, Yi M. The
 association of pretreatment thrombocytosis with prognosis and
 clinicopathological significance in cervical cancer: a systematic review and
 meta-analysis. Oncotarget. 2017 Apr 11;8(15):24327-24336.
- 368
 9. Escande A, Haie-Meder C, Maroun P, Gouy S, Mazeron R, Leroy T,
 369
 Bentivegna E, Morice P, Deutsch E, Chargari C. Neutrophilia in locally
 advanced cervical cancer: A novel biomarker for image-guided adaptive
 brachytherapy? Oncotarget. 2016 Nov 15;7(46):74886-74894
- 10.Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK,
 Portelance L, Crook J, Jones KD. The importance of hemoglobin levels during
 radiotherapy for carcinoma of the cervix. Cancer. 1999 Oct 15;86(8):1528-36
- 11. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic
 factors for response to cisplatin-based chemotherapy in advanced cervical
 carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010
 Jan;116(1):44-9
- 12. Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ 3rd, Poveda A, Landrum
 LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH Prospective
 Validation of Pooled Prognostic Factors in Women with Advanced Cervical
 Cancer Treated with Chemotherapy with/without Bevacizumab: NRG
 Oncology/GOG Study. Clin Cancer Res. 2015 Dec 15;21(24):5480-7.

- 13. Kozasa K, Mabuchi S, Komura N, Yokoi E, Hiromasa K, Sasano T, Kawano M,
 Matsumoto Y, Kobayashi E, Kimura T. Comparison of clinical utilities of the
 platelet count and platelet-lymphocyte ratio for predicting survival in patients
 with cervical cancer: a single institutional study and literature review.
 Oncotarget. 2017 Jul 25;8(33):55394-55404
- 14. Chen L, Zhang F, Sheng XG, Zhang SQ, Chen YT, Liu BW Peripheral
 platelet/lymphocyte ratio predicts lymph node metastasis and acts as a
 superior prognostic factor for cervical cancer when combined with neutrophil:
 Lymphocyte. Medicine (Baltimore). 2016 Aug;95(32):e4381
- 15. Zheng RR, Huang XW, Liu WY, Lin RR, Zheng FY, Lin F. Nomogram
 Predicting Overall Survival in Operable Cervical Cancer Patients. Int J
 Gynecol Cancer. 2017 Jun;27(5):987-993
- 16. Okazawa-Sakai M, Mabuchi S, Isohashi F, Kawashima A, Yokoi E, Ogawa K,
 Kimura T. Predictors of distant relapse in patients with FIGO stage IIB-IVA
 cervical cancer treated with definitive radiotherapy. J Obstet Gynaecol Res.
 2017 Nov;43(11):1743-1750
- 17. Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological
 malignancies--a possible tumor-associated marker. J Cancer Res Clin Oncol.
 1986;111(1):54-8.
- 18. Koulis TA, Kornaga EN, Banerjee R, Phan T, Ghatage P, Magliocco AM,
 Lees-Miller SP, Doll CM. Anemia, leukocytosis and thrombocytosis as
 prognostic factors in patients with cervical cancer treated with radical
 chemoradiotherapy: A retrospective cohort study. Clin Transl Radiat Oncol.
 2017 Jun 12;4:51-56
- 408 19.Blanc, B., Finch, C.A., Hallberg, L., Herbert, V., Lawkowicz, W., Layrisse, M.
 409 Nutritional anemias. Report of a WHO Scientific Group. WHO Tech Rep Ser.
 410 1968:1-40.
- 20.Zheng RR, Huang XX, Jin C, Zhuang XX, Ye LC, Zheng FY, Lin F.
 Preoperative platelet count improves the prognostic prediction of the FIGO staging system for operable cervical cancer patients. Clin Chim Acta. 2017
 Oct;473:198-203
- 415 21.INTERLACE A phase III multicentre trial of weekly ... UCL CTC
 416 www.ctc.ucl.ac.uk/TrialDetails.aspx?Trial=89
- 41722.A Phase III trial of adjuvant chemotherapy following ... RTOG) is418https://www.rtog.org/ClinicalTrials/.../StudyDetails.aspx?action
- 23. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial
 of bevacizumab in the treatment of persistent or recurrent squamous cell
 carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol.
 2009 Mar 1;27(7):1069-74.
- 423 24. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM,
 424 Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ,
 425 Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ,
 426 Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for
 427 advanced cervical cancer: final overall survival and adverse event analysis of

- 428 a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology
- 429 Group 240). Lancet. 2017 Oct 7;390(10103):1654-1663.
- 430 25. Chemoradiation Therapy and Ipilimumab in Treating Patients With ...
- 431 https://clinicaltrials.gov/ct2/show/NCT017115

432

433






Figure 2: Overall survival




Table 1: patients' characteristics

Demographic and Baseline Disease and treatment Characteristics					
Baseline characteristics					
Mean age - year	45.9 (±9.9)				
BMI - kg/m2	23.8 (23.1-26.7)				
Tumor histologic type - no (%) Squamous cell carcinoma Adenocarcinoma	189 (80) 48 (20)				
FIGO – no (%) IB IIA IIB III IV	76 (31) 13 (5.5) 122 (51) 18 (7.5) 9 (4)				
Size – no (%) Median size - mm < 40mm 40-50mm >50mm Missing	48.9 (6-120) 30 (12.7) 89 (37.5) 103 (43.5) 15 (6.3)				
Treatment characteristics					
Median time between 1 st consultation and PET scan - day	8.97 (1.75-17)				
Median time between 1 st consultation and surgery* - day	24 (16-32)				
Median time between PET scan and surgery* - day	15 (8-24)				
Median time between surgery and CRT** - day	19 (13-28)				
Positive PET scan – no (%) Pelvic Para aortic Both	89 (37.5) 89 0 0				
Positive nodes (histology) - no	21 (14)				
Completion surgery after brachytherapy - no (%)	16 (6.7)				
Residual disease after surgery*** - no (%)	6 (2.5)				

Table 2 : Relapses' characteristics

Follow up and relapse			
Median follow up – month (range)	53 (48-59)		
Recurrence			
No (%)	53 (22)		
Localization – no (%)			
Pelvic nodes	21 (39)		
Para aortic nodes	10 (18)		
Both	3		
Distant	26 (49)		
carcinosis	6 (11)		
Median time in month	8.24 (0.03-67.9)		
Death			
No(%)	40 (16)		
Median time in month (range)	21 (0.06-92.9)		

Table 3: multivariate analysis

Variable	Category	HR	p	
score	0	1	0.00036	
	1	2.49 [CI 95% 0.72-8.56]		
	2	8.33 [CI 95% 2.39-29.07		
	3	4.92 [CI 95% 1.16-20.91]		
FIGO	IB	1	<0.0001	
stage	II	3.59 [CI 95% 1.44-8.98]		
	III-IV	10.92 [Cl 95% 3.65-32.66]		
Histology	adenocarcinoma	1	0.75	
	squamous cell carcino	0.86 [CI 95% 0.35-2.13]		
	ma			
Age		0.98 [CI 95% 0.95-1.02]	0.32	
Node	negative	1	0.9	
	positive	1.06 [CI 95% 0.44-2.55]		